Cerenetex

GlyTR Therapeutics is an early-stage biotech company based in Irvine, CA, focused on developing a novel class of immunotherapeutic anticancer molecules and cells that are antibody-independent. Their platform technology aims to generate bispecific proteins and chimeric antigen receptor T cells, effectively targeting cancer antigens that are abnormally expressed across various types of cancer. By addressing the limitations of current antibody-based immunotherapies, GlyTR's innovative approach seeks to induce the killing of multiple solid and blood cancers, ranging from breast cancer to leukemia. The company is dedicated to transforming cancer treatment and is eager to collaborate with leaders in cancer care research. Generated from the website

Edwards Lifesciences is one of the world s leaders in advanced cardiovascular disease treatments. The company leverages its research, design, development and marketing expertise to produce products that addresses specific cardiovascular opportunities, including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT and Swan-Ganz. The company has more than 5,000 employees throughout the world. It has manufacturing plants in the U.S., Brazil, Dominican Republic, Japan, Switzerland and Puerto Rico. Edwards Lifesciences is headquartered in Irvine, Calif.